Concentra Group Holdings Parent Inc — AI technical analysis, September 2026
NYSE/NASDAQ · Health Care
AI Recommendation
BUY
Technical score 100/100
Last price: $36.57 · 52W range $18.55 – $36.71
Short answer
Should you buy CON right now? Stockgaide's AI rates CON as
BUY, with a technical score of
100/100 at a last price of $36.57.
The 50-day average is above the 200-day average, and RSI sits at 64.0.
Wall Street's consensus rating is 1.85/5.
Full AI analysis for CON
Strategic Conclusion
Recommendation: Buy
Why? The stock is trading just below its 52-week high with a clear medium-term uptrend (SMA50 above SMA200), a technical score of 80/100, and strong analyst support (12 buy ratings vs. 1 hold). The P/E of 22.43 is reasonable for a profitable healthcare services company, and momentum remains positive despite a slight MACD caution flag.
Ideal profile: Growth-oriented investor comfortable with moderate volatility; short-term traders can also play the breakout above $36.05.
Price range: Entry zone $34.50–$35.80; next resistance at $36.05; upside target $40.00; stop-loss at $32.80 (below SMA50).
Practical action: Buy on dips toward $34.50–$35.00 or on a confirmed daily close above $36.05. Reduce or exit if price closes below $33.00.
1. Recent Price & Momentum
Current price $35.81 is only 0.7% below the 52-week high of $36.05 and far above the 52-week low of $18.55 — clearly near the top of its range.
This is a strong uptrend, but the proximity to the high means a breakout or a short-term pullback are both possible.
Short-term scenario: a close above $36.05 could trigger acceleration; failure to break may lead to a retest of SMA50 around $33.08.
2. Valuation (P/E)
P/E TTM of 22.43 is moderate for a healthcare services company with a $4.57B market cap.
The price already reflects solid recovery expectations, but it is not extreme; future earnings growth is needed to justify further multiple expansion.
At current levels, valuation is not a barrier to buying, but it does limit the margin of safety.
3. Technical Analysis
SMA50 ($33.08) is well above SMA200 ($25.56) — golden-cross territory and confirmation of a medium-term uptrend.
RSI at 58.3 is neutral, leaving room to run before overbought conditions.
MACD (0.4781) is slightly below its signal line (0.5063) with a negative histogram (-0.0282), indicating a minor short-term momentum pause.
Technical Score: 80/100 → BUY, supported by trend structure despite the MACD caution.
4. Analyst Consensus
Mean analyst rating is 1.85/5 with 12 buy and 1 hold — a strong bullish consensus.
This aligns well with the technical uptrend and price action; only the MACD divergence suggests the market may need a few sessions to catch up.
Overall, analysts and technicals point in the same direction: buy on strength, but with disciplined risk management near the 52-week high.
Technical signal details
Rule-based read from price and momentum indicators only — the score behind the AI's recommendation above. Technical score: 100/100 (BUY).
50-day moving average is above the 200-day — medium-term uptrend (golden-cross territory).
MACD is above its signal line — bullish momentum.
RSI at 64.01 — neutral momentum.
Wall Street consensus rating of 1.85 — analysts lean Buy.
Stockgaide's AI currently rates CON as BUY, with a technical score of 100 out of 100 at a last price of $36.57. This is educational content, not investment advice.
Is CON in an uptrend?
CON's 50-day moving average (33.25) is above its 200-day moving average (25.71), which points to a medium-term uptrend.
What is CON's RSI today?
CON has a 14-day RSI of 64.0, which places it in neutral territory (above 70 is overbought, below 30 is oversold).
What do analysts say about CON?
Wall Street analysts covering CON have a consensus rating of 1.85 out of 5 (1 = Strong Buy), meaning they lean Buy — 12 Buy · 1 Hold · 0 Sell.
Where is CON trading in its 52-week range?
CON last traded at $36.57, against a 52-week range of $18.55 to $36.71 — about 99% of the way up that range.
Get the full AI analysis of CON
Price targets, fundamentals deep-dive and an AI-written report — free, no signup.